866-997-4948(US-Canada Toll Free)

Crohns Disease (Regional Enteritis) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 386 Pages

Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2017, provides an overview of the Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline landscape.

Crohns disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohns disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 12, 25, 25, 38, 15 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 2 molecules, respectively.

Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Crohn's Disease (Regional Enteritis) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Crohn's Disease (Regional Enteritis) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis) (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Regional Enteritis) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 6
Crohn's Disease (Regional Enteritis) - Overview 7
Crohn's Disease (Regional Enteritis) - Therapeutics Development 8
Crohn's Disease (Regional Enteritis) - Therapeutics Assessment 25
Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development 37
Crohn's Disease (Regional Enteritis) - Drug Profiles 78
Crohn's Disease (Regional Enteritis) - Dormant Projects 352
Crohn's Disease (Regional Enteritis) - Discontinued Products 360
Crohn's Disease (Regional Enteritis) - Product Development Milestones 362
Appendix 372

List of Tables
Number of Products under Development for Crohn's Disease (Regional Enteritis), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by 4D Pharma PLC, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by AB Science SA, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by AbbVie Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Adello Biologics LLC, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Aerpio Therapeutics Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Alfa Wassermann SpA, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Allergan Plc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Alpha Cancer Technologies Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Alteogen Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Amgen Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Anterogen Co Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Aptevo Therapeutics Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by ARA Healthcare Pvt Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Arven Ilac, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Atlantic Bio Sci LLC, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Bioleaders Corp, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by BioLingus AG, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Bristol-Myers Squibb Company, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Celgene Corp, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Celltrion Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by ChemoCentryx Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by ChironWells GmbH, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Coherus BioSciences Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Commence Bio Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Concenter BioPharma Silkim Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by DBV Technologies SA, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by EA Pharma Co Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Eisai Co Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Eli Lilly and Company, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Enterome Bioscience SA, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Enzo Biochem Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Ferring International Center SA, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Formycon AG, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Galapagos NV, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Genentech Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Genor BioPharma Co Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by iCo Therapeutics Inc., H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Immune Response BioPharma Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Inception Sciences Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Innovent Biologics Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Johnson & Johnson, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Jyant Technologies Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Kang Stem Biotech Co Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by KPI Therapeutics Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Merck & Co Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Merck KGaA, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Mesoblast Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Momenta Pharmaceuticals Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Mycenax Biotech Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Novartis AG, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Oncodesign SA, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Panacea Biotec Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Pfenex Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Protagonist Therapeutics Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Protalix BioTherapeutics Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Qu Biologics Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Re-Pharm Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by RedHill Biopharma Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by SATT North SAS, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Second Genome Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Shire Plc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Sigmoid Pharma Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Soligenix Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Stelic Institute & Co Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Synedgen Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Synlogic Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by The Cell-Factory BVBA, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Tiziana Life Sciences Plc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Ventria Bioscience, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Virobay Inc, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Vivelix Pharmaceuticals Ltd, H2 2017
Crohn's Disease (Regional Enteritis) - Pipeline by Xbrane Biopharma AB, H2 2017
Crohn's Disease (Regional Enteritis) - Dormant Projects, H2 2017
Crohn's Disease (Regional Enteritis) - Dormant Projects, H2 2017 (Contd..1), H2 2017
Crohn's Disease (Regional Enteritis) - Dormant Projects, H2 2017 (Contd..2), H2 2017
Crohn's Disease (Regional Enteritis) - Dormant Projects, H2 2017 (Contd..3), H2 2017
Crohn's Disease (Regional Enteritis) - Dormant Projects, H2 2017 (Contd..4), H2 2017
Crohn's Disease (Regional Enteritis) - Dormant Projects, H2 2017 (Contd..5), H2 2017
Crohn's Disease (Regional Enteritis) - Dormant Projects, H2 2017 (Contd..6), H2 2017
Crohn's Disease (Regional Enteritis) - Dormant Projects, H2 2017 (Contd..7), H2 2017
Crohn's Disease (Regional Enteritis) - Discontinued Products, H2 2017
Crohn's Disease (Regional Enteritis) - Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures
Number of Products under Development for Crohn's Disease (Regional Enteritis), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *